Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 11/20 | 0.55 |
| ▸ | CA2 | P00918 | 11/20 | 0.55 |
| ▸ | CA9 | Q16790 | 10/20 | 0.55 |
| ▸ | CA12 | O43570 | 1/20 | 0.55 |
| ▸ | CA3 | P07451 | 1/20 | 0.55 |
| ▸ | CA4 | P22748 | 1/20 | 0.55 |
| ▸ | CA6 | P23280 | 1/20 | 0.55 |
| ▸ | CA5A | P35218 | 1/20 | 0.55 |
| ▸ | CA7 | P43166 | 1/20 | 0.55 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.55 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.55 |
| ▸ | LPL | P06858 | 3/20 | 0.44 |
| ▸ | LIPG | Q9Y5X9 | 3/20 | 0.44 |
| ▸ | BRPF1 | P55201 | 1/20 | 0.43 |
| ▸ | ALPL | P05186 | 1/20 | 0.38 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL190423 | 0.85 | CA1 (0.73) | CA1CA2CA9CA12CA3 | |
| SCHEMBL393567 | 0.82 | CA1 (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL31438926 | 0.82 | CA1 (0.50) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17379035 | 0.80 | CA12 (0.40) | CA1CA2CA9CA12CA3 | |
| SCHEMBL29644319 | 0.79 | LPL (0.62) | CA1CA2CA9CA12CA3 | |
| SCHEMBL1293460 | 0.79 | LPL (0.62) | CA1CA2CA9CA12CA3 | |
| SCHEMBL12619815 | 0.79 | LPL (0.49) | CA1CA2CA9CA12CA3 | |
| SCHEMBL17378988 | 0.79 | CA1 (0.47) | CA1CA2CA9CA12CA3 | |
| SCHEMBL21314553 | 0.79 | CA1 (0.51) | CA1CA2CA9CA12CA3 | |
| SCHEMBL12314741 | 0.77 | CA1 (0.51) | CA1CA2CA9CA12CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112778216-A | Sulfonamide compound, preparation method and application | 王玉珍 | 2021-05-11 | — | — | CN | disclosed |
| CN-112239461-A | Dihydroisobenzofuran compound and application thereof in preventing and treating senile dementia | 杨军红 | 2021-01-19 | — | — | CN | disclosed |
| CN-111518036-A | Preparation method of Dasabovir key intermediate | 杭州勇诚睿生物科技有限公司 | 2020-08-11 | — | — | CN | disclosed |
| US-9637478-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2017-05-02 | — | — | US | disclosed |
| EP-2411352-B1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBVIE INC (US) | 2017-01-18 | — | — | EP | disclosed |
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES | 2016-12-22 | — | — | US | disclosed |
| EP-2639226-B1 | Anti-infective pyrimidines and uses thereof | ABBVIE BAHAMAS LTD (BS) | 2016-08-31 | — | — | EP | disclosed |
| US-9353091-B2 | Antiviral compounds and uses thereof | ABBVIE INC. (US) | 2016-05-31 | — | — | US | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
| WO-2015197028-A1 | COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND USES THEREOF IN MEDICINE | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2015-12-30 | — | — | WO | disclosed |
| WO-2010111436-A2 | ANTIVIRAL COMPOUNDS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2010-09-30 | — | — | WO | disclosed |
| EP-2222646-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| EP-2203431-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | Abbott Laboratories (US) | 2010-07-07 | — | — | EP | disclosed |
| WO-2010072598-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | STEINER SANDRA | 2010-06-24 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160368905-A1 | ANTIVIRAL COMPOUNDS AND USES THEREOF | MAVS, ZC3HAV1, EIF2AK2 | CA1 3987/4885CA2 3738/4885CA9 2794/4885 |
| US-20100158860-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | RFC1, RRP1B, RRBP1 | CA1 4826/4885CA2 4862/4885CA9 4714/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | CA1 2881/4885CA2 1429/4885CA9 1841/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.